ALN HTT02
Alternative Names: ALN-HTT-02Latest Information Update: 22 May 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Huntingtin protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Huntington's disease